Atlas Trials

A Study of Galunisertib on the Immune System in Participants With Cancer

Clinical trial NCT02304419 · COMPLETED

Trial details

NCT number
NCT02304419
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Neoplasm
Start date
2015-05-01
Primary completion
2016-08-01
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.